Effect of Imatinib on Suppression of Malaria Parasites in Patients With

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.

Clinical Trial Description

An exploratory study to examine the efficacy and safety of imatinib mesylate in combination with dihydroartemisinin plus piperaquine on suppression of parasitemia in patients with uncomplicated Plasmodium falciparum malaria. In vitro studies of P. falciparum parasitized erythrocytes demonstrate that inhibitors of the protein tyrosine kinase SYK prevent malaria parasite egress from infected red blood cells and thereby terminate the parasite's life cycle. Although no potent syk kinase inhibitors were approved for human use at the time of initiation of this study, a bcr-abl tyrosine kinase inhibitor (imatinib mesylate (Gleevec®)) that also exhibits off-target inhibition of syk tyrosine kinase, has been FDA-approved for treatment of a number of human malignancies including chronic myelogenous leukemia and GIST. Because imatinib can be taken daily for many years without significant toxicity, it can be used to obtain a preliminary indication of whether inhibition of erythrocyte syk kinase can suppress parasitemia in patients with P. falciparum malaria. In a phase 1 clinical trial on the same patient population, anti-malaria activity was observed with imatinib, with little or no accompanying toxicity. Because dihydroartemisinin plus piperaquine constitute the currently used standard-of-care therapy for malaria in Southeast Asia, the above trial will test the safety and efficacy of the combination of imatinib plus dihydroartemisinin and piperaquine in treatment of uncomplicated malaria. In this pilot study, the rate of decrease in peripheral blood parasitemia in 30 adult male patients with uncomplicated malaria will be compared to the same rate of decrease in parasitemia in 30 adult male patients treated solely with dihydroartemisinin plus piperaquine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02614404
Study type	Interventional
Source	HuLow
Contact
Status	Completed
Phase	Phase 1
Start date	November 2015
Completion date	February 2, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04577066` - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.	Phase 1/Phase 2
Completed	`NCT01883609` - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S	Phase 1/Phase 2
Completed	`NCT00593398` - Malarial Immunity in Pregnant Cameroonian Women
Completed	`NCT01659281` - Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand	N/A
Completed	`NCT00074841` - Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India	Phase 2/Phase 3
Recruiting	`NCT04416945` - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic	N/A
Completed	`NCT00314899` - Fetal Immunity to Falciparum Malaria
Completed	`NCT02867059` - SJ733 Induced Blood Stage Malaria Challenge Study	Phase 1
Completed	`NCT00701961` - Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy	Phase 2/Phase 3
Completed	`NCT00338520` - Hyperphenylalaninemia in Cerebral Malaria	N/A
Completed	`NCT00707200` - The Cytoadherence in Pediatric Malaria (CPM) Study	N/A
Completed	`NCT00393757` - Malaria Transmission and Immunity in Highland Kenya
Completed	`NCT03783299` - Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic	Phase 4
Completed	`NCT00358332` - Phase I Pediatric FMP2.1/AS02A Trial in Mali	Phase 1
Completed	`NCT00730782` - Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers	Phase 1
Completed	`NCT00349713` - FMP2.1 Trial in Bandiagara, Mali	Phase 1
Recruiting	`NCT05052502` - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand	N/A
Completed	`NCT04093765` - Mass Screening and Treatment for Reduction of Falciparum Malaria	N/A
Completed	`NCT03764527` - Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar	Phase 4
Completed	`NCT03773536` - Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria — MIM

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms